Psychopharmacology and Psychiatry Updates
Psychopharmacology Institute
- 8 minutes 52 secondsBeyond Weight Loss: Can Semaglutide Treat Alcohol Use Disorder?
In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD.
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.
1 April 2026, 4:00 pm - 14 minutes 12 secondsManaging Lithium's Renal Risks: Evidence-Based Strategies
In this episode, we explore lithium's renal side effects with Dr. David Osser from Harvard Medical School. How can we keep patients safe while using this highly effective medication? Discover the real risk numbers, prevention strategies, and evidence-based monitoring approaches that protect kidney function long-term.
Faculty: David Osser, M.D. Host: Richard Seeber, M.D.
27 March 2026, 4:00 pm - 18 minutes 34 secondsCariprazine for Bipolar Illness in the Elderly: What the Data Show
In this episode, we explore cariprazine's efficacy and safety in older adults with bipolar I disorder. Does age change how we should dose this medication? Discover evidence-based insights on treating both depression and mania in elderly patients, plus critical pearls on monitoring for akathisia.
Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.
22 March 2026, 4:00 pm - 17 minutes 28 secondsLithium Essentials: Monitoring, Drug Interactions, and Safety
In this episode, we explore essential baseline testing, monitoring protocols, and optimal dosing strategies for lithium with Dr. David Osser from Harvard Medical School. Why does giving lithium once daily at night actually protect the kidneys better than divided doses? Discover evidence-based approaches that could transform your lithium prescribing practice.
Faculty: David Osser, M.D. Host: Richard Seeber, M.D.
17 March 2026, 4:00 pm - 9 minutes 29 secondsADHD Stimulants: Clinical Safeguards Against Misuse and Diversion
In this episode, we explore the delicate balance of prescribing stimulants for adult ADHD when abuse potential is a concern. How do you distinguish between performance-driven misuse and recreational abuse? Dr. Bukstein shares essential red flags, safety precautions, and strategies to protect both patients and prescribers.
Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D.
12 March 2026, 4:00 pm - 9 minutes 9 secondsStaying Well: LAIs vs. Oral Medications in Cannabis-Induced Psychosis
In this episode, we explore groundbreaking research on treating cannabis-induced psychosis with antipsychotic medications. Which formulations cut hospitalization rates by 75%? And why do some commonly prescribed antipsychotics show no effectiveness at all in preventing future psychotic episodes?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.
7 March 2026, 5:00 pm - 13 minutes 25 secondsAdult ADHD: Optimizing Stimulant Therapy
In this episode, we explore stimulant medications for adult ADHD with Dr. Oscar Bukstein. Why have amphetamines overtaken methylphenidate as the most prescribed option? Discover how to match formulation duration to patient needs, navigate cardiovascular risks, and monitor treatment effectively for optimal outcomes in adult ADHD management.
Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D.
2 March 2026, 5:00 pm - 12 minutes 51 secondsSemaglutide for Clozapine-Induced Weight Gain: The COaST Trial
In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
25 February 2026, 5:00 pm - 8 minutes 39 secondsBeyond Stimulants: Tailoring ADHD Treatment to Comorbidities
In this episode, we explore the treatment algorithm for adult ADHD with Dr. Oscar Bukstein from Harvard Medical School. Should you start with stimulants or non-stimulants when substance use disorder complicates the picture? Discover how comorbidities like depression and anxiety reshape your medication selection strategy for optimal patient outcomes.
Faculty: Oscar G. Bukstein, M.D., M.P.H Host: Richard Seeber, M.D.
20 February 2026, 5:00 pm - 12 minutes 59 secondsBeyond Standard Treatment: Exploring Pramipexole in Bipolar Depression
In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications.
Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.
15 February 2026, 5:00 pm - 6 minutes 42 secondsSERT Gene Testing: Separating Hype from Evidence
In this episode, we explore the controversial role of SERT gene testing in predicting SSRI response with Dr. Chris Aiken. Can genetic testing really tell us which patients will respond to antidepressants, or are we putting too much faith in pharmacogenetic promises that lack solid evidence?
Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D.
10 February 2026, 5:00 pm - More Episodes? Get the App